Clinical trials: Leukoderma
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04057573
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 76 sites in United States, Bulgaria and 7 more
- Volunteers
- 344 people
- Sponsor
- Incyte Corporation
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04052425
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who…
- Trial name
- NCT04530344
- Testing
- ruxolitinib, Vehicle
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 458 people
- Sponsor
- Incyte Corporation
Vitiligo
Investigating Healthcare Disparities in Vitiligo
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are…
- Trial name
- NCT06097494
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 39,374 people
- Sponsor
- Momentum Data
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Albinism, Oculocutaneous Albinism
Vision Response to Dopamine Replacement
The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral…
- Trial name
- NCT01663935
- Testing
- Levodopa/carbidopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial)…
- Trial name
- NCT05247489
- Testing
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Where
- 13 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Albinism
Trial of L-DOPA as a Treatment to Improve Vision in Albinism
This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism.
- Trial name
- NCT01176435
- Testing
- Levodopa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota